- Home
- CBRL vs VRDN Comparison
CBRL vs VRDN Comparison
Compare CBRL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRL
- VRDN
- Stock Information
- Founded
- CBRL 1969
- VRDN 2006
- Country
- CBRL United States
- VRDN United States
- Employees
- CBRL N/A
- VRDN N/A
- Industry
- CBRL Restaurants
- VRDN Medical Specialities
- Sector
- CBRL Consumer Discretionary
- VRDN Health Care
- Exchange
- CBRL Nasdaq
- VRDN Nasdaq
- Market Cap
- CBRL 1.3B
- VRDN 1.3B
- IPO Year
- CBRL N/A
- VRDN N/A
- Fundamental
- Price
- CBRL $61.08
- VRDN $14.49
- Analyst Decision
- CBRL Hold
- VRDN Strong Buy
- Analyst Count
- CBRL 8
- VRDN 11
- Target Price
- CBRL $53.86
- VRDN $38.50
- AVG Volume (30 Days)
- CBRL 1.3M
- VRDN 718.6K
- Earning Date
- CBRL 06-05-2025
- VRDN 08-07-2025
- Dividend Yield
- CBRL 1.65%
- VRDN N/A
- EPS Growth
- CBRL N/A
- VRDN N/A
- EPS
- CBRL 2.58
- VRDN N/A
- Revenue
- CBRL $3,510,062,000.00
- VRDN $302,000.00
- Revenue This Year
- CBRL $1.97
- VRDN N/A
- Revenue Next Year
- CBRL $1.61
- VRDN $17,102.33
- P/E Ratio
- CBRL $23.46
- VRDN N/A
- Revenue Growth
- CBRL 2.84
- VRDN 4.86
- 52 Week Low
- CBRL $33.86
- VRDN $9.90
- 52 Week High
- CBRL $65.43
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- CBRL 58.45
- VRDN 50.32
- Support Level
- CBRL $59.74
- VRDN $14.11
- Resistance Level
- CBRL $63.71
- VRDN $16.05
- Average True Range (ATR)
- CBRL 3.16
- VRDN 0.74
- MACD
- CBRL 0.09
- VRDN -0.13
- Stochastic Oscillator
- CBRL 77.64
- VRDN 20.18
About CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The restaurants of the company are open for breakfast, lunch, and dinner, with menus that offer home-style country food. The company generates maximum revenue from the Restaurants.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).